


a

Alignment search: beta-arrestin-1 isoformA (ARRB1) and beta-arrestin-2 isoform3 (ARRB2)




b

		Percent Identity	E value
beta-arrestin-1 Isoform A	beta-arrestin-2 Isoform 1	76.14%	0
	2	73.25%	0
	3	72.48%	0
	4	80.46%	8.00×10 ⁻¹⁵⁰
	5	74.00%	0
	6	71.19%	0
	7	73.09%	4.00×10 ⁻¹¹²

		Percent Identity	E value
beta-arrestin-1 Isoform B	beta-arrestin-2 Isoform 1	77.64%	0
	2	74.69%	0
	3	73.83%	0
	4	80.46%	9.00×10 ⁻¹⁵³
	5	75.42%	0
	6	72.55%	0
	7	75.81%	4.00×10 ⁻¹¹⁵

Extended data Figure 1. Homology in amino acid sequence between β-arrestin 1 and 2, as searched by BLAST in the NCBI database.


a. Alignment search between β-arrestin 1 isoform A and β-arrestin 2 isoform 3 as a representative diagram. BOXSHADE version 3.21 was used. b. β-arrestin 1 isoform A and B were compared with β-arrestin 2 isoforms.

a**b**

Edited genome

1bp Ins : T GTG GAC CAC ATC GAC CCT CGT GG

T G T G G A C C A C C A T C G A C C C T C G T G G



Amino Acid Sequence

WT allele:


VDHIDLVPVDGVVLVDPE

Mutated allele:

VDHIDPRGPCGWCPPGS*

c


Immunoblotting



Extended data Figure 2. Genetic depletion of β -arrestin 1 in SH-SY5Y cells with use of CRISPR/Cas9.

The gRNA design (a) as well as obtained genomic and amino acid sequence (b) for establishing knockout cell lines using CRISPR/Cas9. Western blotting analysis was conducted to confirm the loss of β -arrestin 1 expression.




Extended Data Figure 3



Extended data Figure 3. Genetic depletion of β -arrestin 2 in SH-SY5Y cell with use of CRISPR/Cas9.

The gRNA design (a) as well as obtained genomic and amino acid sequence (b) for establishing knockout cell lines using CRISPR/Cas9. Western blotting analysis was performed to confirm the loss of β -arrestin 2 expression.


a * SH-SY5Y cells whose background is lacking β -arrestin 2 (The detail is shown in Extended Data 3).



Extended data Figure 4 Genetic depletion of both β -arrestin 1 and 2 simultaneously in SH-SY5Y cell with use of CRISPR/Cas9.


The gRNA design (a) as well as obtained genomic and amino acid sequence (b) for establishing knockout cell lines using CRISPR/Cas9. Western blotting analysis was used to confirm the simultaneous loss of expression of both β -arrestin 1 and 2.

Extended Data Figure 5




Extended data Figure 5 MOP internalisation in β -arrestin deficient cell line at an earlier time point on stimulation with DAMGO or Morphine.

MOP internalisation under the simultaneous loss of both β -arrestin 1 and 2, or either one of the β -arrestins in SH-SY5Y cells overexpressing HA-tagged MOR1 upon stimulation with 10 μ M of DAMGO (left panel) or morphine (right panel) as indicated for 10 min.



Extended data Figure 6. Endogenous MOP drives MAPK signalling almost comparably to ectopically overexpressed MOP in SH-SY5Y cells.


a. Receptor internalisation when wild-type or mutated MOP tagged with HA sequence were transfected into SH-SY5Y cells and stimulated with 10 μ M of DAMGO for 10 min (** $P < 0.01$, **** $P < 0.0001$). b. The expression level of wild-type or mutated MOP expressed in SH-SY5Y cells was analysed by immunoblotting. c. Immunoblot analysis of MAPK activation in whole-cell lysates from SH-SY5Y cells stably expressing wild-type MOP (left) in comparison with the parental cells (right).



Extended data Figure 7 Ectopical expression system discerns the signals from stably expressed MOP in HEK293 cells.

Immunoblot analysis of MAPK activation in whole-cell lysates from HEK293 cells stably expressing wild-type MOP (right) in comparison with the parental cells (left).


Extended Data Figure 8




Extended data Figure 8. Genetic depleting of β 2-adaptin with CRISPR/Cas9 in SH-SY5Y cells.

The gRNA design (a) as well as obtained genomic and amino acid sequence (b) for establishing knockout cell lines using CRISPR/Cas9. c. Western blotting analysis was conducted to confirm the loss of expression of the β 2-adaptin subunit of the AP2 adaptor complex.


a Clathrin heavy chain (CLTC)



b TA Cloning



c Immunoblotting



Extended data Figure 9. Introducing mutation on clathrin heavy chain with CRISPR/Cas9.

The gRNA design (a) as well as obtained genomic and amino acid sequence (b) for establishing knockout cell lines using CRISPR/Cas9. c. Western blotting analysis was performed to confirm the reduction of the expression level of clathrin heavy chains. Sample of cell cultures obtained by the knockdown method were used as references.